Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML

Keyphrases

• Phosphorylation 100%
• Acute Myeloid Leukemia 100%
• Acquired Resistance 100%
• FLT3-ITD 100%
• Allosteric Inhibitor 100%
• SHP2 100%
• SHP2 Inhibitor 40%
• Acute Myeloid Leukemia Cells 30%
• SHP099 30%
• Clinical Application 20%
• FMS-like Tyrosine Kinase 3 (FLT3) 20%
• ERK Phosphorylation 20%
• Leukemia Cell Lines 20%
• Tumor 10%
• Combination Therapy 10%
• Clinical Trials 10%
• Mouse Model 10%
• Open Conformation 10%
• Inhibitor Therapy 10%
• Cell Proliferation 10%
• MEK-ERK Pathway 10%
• Receptor Tyrosine Kinase 10%
• Cell Survival 10%
• Cell Growth 10%
• Acute Lymphoblastic Leukemia Cells 10%
• Drug Combination 10%
• Dual Inhibition 10%
• Quantitative Mass Spectrometry 10%
• Phosphoproteomics 10%
• Tyrosine 10%
• Tyrosine Phosphorylation 10%
• Clonogenic 10%
• Oncogenic Transformation 10%
• Label-free 10%
• Overactivation 10%
• Leukemia Mice 10%
• ERK Activation 10%
• Resistant Cells 10%
• FLT3 mutation 10%
• Normal Bone Marrow 10%
• B-cell Acute Lymphoblastic Leukemia (B-ALL) 10%
• Inhibitor Combination 10%
• Inv(16) 10%
• Feedback-based 10%
• Bone Marrow Progenitor Cells 10%
• Isobaric Labeling 10%
• Internal Tandem Duplication 10%
• Adaptive Resistance 10%
• FLT3 Receptor 10%
• Combinatorial Inhibition 10%
• Ras-ERK 10%
• Protein Tyrosine Phosphatase SHP2 10%
• Free Labeling 10%
• Allosteric Inhibition 10%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• Conformation 33%
• Eicosanoid Receptor 16%
• Clinical Trial 16%
• Mouse Model 16%
• Cell Proliferation 16%
• Receptor Tyrosine Kinase 16%
• B Cell 16%
• Cell Survival 16%
• Cell Growth 16%
• Mass Spectrometry 16%
• Protein Tyrosine Phosphatase 16%
• Phosphoproteomics 16%
• Tyrosine Phosphorylation 16%
• Tyrosine 16%
• Rebound 16%
• Isobaric Labeling 16%